Quarterly report pursuant to Section 13 or 15(d)

License and Collaboration Agreement (Details)

v3.22.2.2
License and Collaboration Agreement (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Aug. 17, 2021
Dec. 17, 2020
Sep. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Sep. 15, 2022
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenues     $ 55,779   $ 14,667 $ 105,595 $ 22,201  
Research and development     10,973   20,066 35,118 39,990  
Product Sales                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenues     25,502   $ 14,638 75,142 $ 22,113  
License Agreement Terms | Otuska                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Upfront payments received   $ 50,000            
Potential regulatory milestone revenue   $ 50,000            
Triggered milestone, payments               $ 30,000
License Agreement Terms | Otuska | Service Revenue                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenues     $ 200     $ 400    
License Agreement Terms | Otuska | Minimum                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Tiered royalty percentages on future sales   10.00%            
License Agreement Terms | Otuska | Maximum                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Tiered royalty percentages on future sales   20.00%            
License Agreement Terms | Riptide Bioscience, Inc.                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Upfront license fee $ 6,000              
Research and development       $ 4,000